(24/7 MARKET NEWS) – Windtree Therapeutics, Inc. (NASDAQ: WINT) is active, in this morning’s premarket, after reporting, after yesterday’s market close, that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629).
Windtree, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, is at $0.376, $0.055 higher (+17.23%), on 11 million shares traded.
It needs to break through the 42-cent range on strong volume. It popped and hit 89 cents about 5 weeks ago, and its 52-week range is $0.2751 to $2.37.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.